Novartis quietly returns a key antibiotic to US market
There is some good news in the world of antibiotics. Novartis quietly snagged supplemental FDA approval for its drug Lamprene over the summer, transitioning a decades-old leprosy drug to the commercial market, which may boost ...
October 13, 2026 02:51 PM EDT R&DFDA+ Novartis gives infectious disease docs a boost with antibiotic approval Max Bayer Senior Reporter There is some good news in the world of antibiotics. Novartis quietly snagged supplemental FDA approval for its drug Lamprene over the summer, transitioning a … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that